Thymosin Alfa 1 in Recipients of Allogeneic Hematopoietic Transplantation for Hematological Malignancies
Recruitment status was: Not yet recruiting
The purpose of this trial is to determine safety and efficacy of 16 weeks treatment with thymosin alpha 1 given at 1.6 mg dose once daily by subcutaneous injection in adult patients with hematological undergone allogenic bone marrow transplantation and CMV positive.
The efficacy will be explored assessing the ability of thymosin alpha1 to prevent the infection complications.
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Phase I/II Clinical Trial on Thymosin Alfa 1 of Allogeneic Hematopoietic Transplantation|
- Efficacy in terms of improvement of immunological reconstitution, infectious mortality; safety as prevention of GvHD. [ Time Frame: 3 years ]
|Study Start Date:||December 2007|
|Estimated Study Completion Date:||December 2010|
|Primary Completion Date:||December 2007 (Final data collection date for primary outcome measure)|
|No Intervention: 2|
Drug: Thymosin alpha 1
1.6 mg sc once a day for 16 weeks
This is an open label, monocenter, explorative study . A total of 9 patients will be included in the study in three sequential cohort of 3 patients each. Patients will enter into the study after meeting the inclusion and exclusion criteria and signing the Informed Consent Form.
The first three patients will be treated for 16 weeks starting 40 days after transplantation; if all three patients will complete the treatment period without any serious treatment related adverse event then the recruitment of second cohort of patients will be opened and patients treated starting from 20 days after transplantation. The same procedure will be applied for the third cohort of patients starting treatment from day of transplantation.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00580450
|Hematology Section, University of Perugia|
|Perugia, Italy, 06122|
|Principal Investigator:||Andrea Velardi, Prof||Hematology Section, University of Perugia|